Phase I oncology trials incorporating patient choice of dose

BACKGROUND: Patients recruited in phase I oncology trials are often treated at doses lower than the maximum tolerated dose (MTD), and therefore may not receive the most efficacious dose available, despite their expectations to the contrary. This report investigates the consequences of allowing a pat...

Descripción completa

Detalles Bibliográficos
Autor principal: Huson, L W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461169/
https://www.ncbi.nlm.nih.gov/pubmed/22929891
http://dx.doi.org/10.1038/bjc.2012.378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461169/
https://www.ncbi.nlm.nih.gov/pubmed/22929891
http://dx.doi.org/10.1038/bjc.2012.378

Ejemplares similares